In Brief: Immunomedics
This article was originally published in The Gray Sheet
Executive Summary
Immunomedics: Firm's CEA-Scan colorectal diagnostic imaging agent shows 60% accuracy in predicting tumor resectability in patients with known or suspected recurrent colorectal cancer, compared to 47% for computed tomography alone, according to data presented May 23 at a meeting of the American Society of Clinical Oncologists in Los Angeles. The results are part of a Phase III, 208-patient study conducted in response to FDA's May 1994 request for data to supplement the company's product license application submitted in 1991 ("The Gray Sheet" March 27, p. 39). The study results were submitted to FDA in March...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.